{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000721","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2026-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.565256+00:00","generated_at":"2026-05-16T03:31:01.080226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Harvard Bioscience preliminary Q4 revenue $23.7M, adj EBITDA $3.8M, 27% YoY growth","bullets":["Preliminary Q4 revenue $23.7M, above guidance midpoint; gross margin 60% at high end of 58-60% range.","Adjusted EBITDA $3.8M, up 27% YoY, driven by cost reductions and expense management.","2026 outlook: year-over-year revenue growth and mid-to high-single-digit adjusted EBITDA growth.","Strategy focuses on translational science tools, consumables expansion (55% recurring revenue), and operational excellence.","Full Q4 and FY2025 results to be released March 12, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000721","json":"https://secwatch.observer/filing/0001171843-26-000721.json","markdown":"https://secwatch.observer/filing/0001171843-26-000721.md","text":"https://secwatch.observer/filing/0001171843-26-000721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326000721/0001171843-26-000721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326000721/f8k_020926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:31:01.080226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}